Therefore, the present study suggested that cisatracurium besilate enhanced the TRAIL-induced apoptosis of GC cells via p53 signaling, and the synergistic effects of cisatracurium besilate and TRAIL increased the sensitivity of TRAIL to amplify the therapeutic efficacy in GC management. This evidence concerns the gene TP53 and gastric cancer.